What is NuProbe?
NuProbe is at the forefront of genomics and molecular diagnostics, developing groundbreaking technologies designed to enhance the sensitivity of sequencing mutations and copy number variations by over tenfold. With operational sites in Houston, USA, and Shanghai and Suzhou, China, NuProbe is dedicated to advancing precision medicine. The company's vision is to make accurate disease state information accessible and timely, ultimately improving patient outcomes. Its current product and service offerings are designated for Research Use Only and are not intended for In Vitro Diagnostic applications.
How much funding has NuProbe raised?
NuProbe has raised a total of $58.3M across 3 funding rounds:
Series A
$11M
Unspecified
$42M
Unspecified
$5.3M
Series A (2018): $11M, investors not publicly disclosed
Unspecified (2021): $42M led by Biotrack Capital, Taifu Capital, Tuobang Capital, Yonghua Capital, Juming Capital, and Panlin Capital
Unspecified (2022): $5.3M, investors not publicly disclosed
Key Investors in NuProbe
Biotrack Capital
Biotrack Capital is a venture capital firm likely specializing in investments within the biotechnology and healthcare sectors, given its domain.
Yonghua Capital
Shanghai Yonghua Investment Management Co Ltd is a private equity investment firm focused on enhancing the value of Chinese enterprises, indicating a strategic interest in NuProbe's operations within China.
Taifu Capital
Taifu Capital is an investment firm that has participated in NuProbe's funding rounds, suggesting a strategic interest in the company's growth and technological advancements.
What's next for NuProbe?
The substantial enterprise-level funding NuProbe has garnered, particularly the recent strategic investment, positions the company for accelerated growth and market expansion. This capital will likely fuel further research and development into its proprietary diagnostic technologies, potentially enabling broader clinical applications and partnerships. The company's focus on improving diagnostic sensitivity aligns with the growing demand for precision medicine, suggesting a trajectory towards becoming a key player in the molecular diagnostics landscape. Future developments may include scaling manufacturing capabilities, expanding its global footprint, and navigating regulatory pathways for potential diagnostic use.
See full NuProbe company page
